NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
73207-0304-41 | 73207-0304 | Vimseltinib | ROMVIMZA | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
16714-0726-01 | 16714-0726 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jun 15, 2017 | Apr 30, 2020 | In Use |
72485-0215-04 | 72485-0215 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 15, 2020 | In Use | |
42367-0521-25 | 42367-0521 | Bendamustine Hydrochloride | BELRAPZO | 100.0 mg/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jun 3, 2019 | In Use | |
67457-0215-01 | 67457-0215 | Melphalan Hydrochloride | Melphalan Hydrochloride | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 10, 2013 | Jan 31, 2026 | In Use |
70377-0013-22 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sep 4, 2020 | In Use | |
23155-0776-71 | 23155-0776 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 15, 2022 | Jun 15, 2022 | No Longer Used |
63323-0650-20 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 11, 2010 | May 21, 2015 | No Longer Used | |
71288-0166-10 | 71288-0166 | Pemetrexed disodium | Pemetrexed | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
60505-3801-08 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
16714-0886-01 | 16714-0886 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Dec 1, 2018 | In Use | |
68001-0536-41 | 68001-0536 | Pemetrexed | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jul 4, 2022 | In Use | |
69097-0353-78 | 69097-0353 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb 10, 2017 | In Use | |
00069-0136-01 | 00069-0136 | Bosutinib monohydrate, Bosutinib | Bosulif | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
47335-0890-72 | 47335-0890 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
42291-0505-01 | 42291-0505 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct 5, 2020 | In Use | |
82943-0101-05 | 82943-0101 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 1, 2024 | In Use | |
71288-0117-91 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 11, 2020 | In Use | |
10019-0926-02 | 10019-0926 | Ifosfamide | Ifosfamide | 3.0 g/60mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec 30, 1988 | In Use | |
68001-0627-27 | 68001-0627 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 30, 2025 | In Use | |
72603-0103-01 | 72603-0103 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 29, 2019 | In Use | |
72603-0256-01 | 72603-0256 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2024 | In Use | |
70748-0340-01 | 70748-0340 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 1, 2024 | In Use | |
00703-4100-68 | 00703-4100 | Ifosfamide and Mesna | Ifosfamide and Mesna | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Feb 26, 2002 | Feb 25, 2010 | No Longer Used |
Found 11748 results — Export these results